A Broken Heart: Empagliflozin Falls Flat after Acute Myocardial Infarction

https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/04/e1/22/04e122ab-a12d-c183-2d35-1cae1373c023/mza_6262719269478151817.jpg/600x600bb.jpg

iForumRx.org

University of Mississippi School of Pharmacy

100 episodes

1 month ago

We explore the evidence that informs ambulatory care pharmacy practice. Check out our website & podcasts, & consider submitting a commentary!

Medicine

Health & Fitness

RSS

All content for iForumRx.org is the property of University of Mississippi School of Pharmacy and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

We explore the evidence that informs ambulatory care pharmacy practice. Check out our website & podcasts, & consider submitting a commentary!

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/44846472/97acd318209297a0.png

A Broken Heart: Empagliflozin Falls Flat after Acute Myocardial Infarction

iForumRx.org

20 minutes 33 seconds

1 year ago

A Broken Heart: Empagliflozin Falls Flat after Acute Myocardial Infarction

Despite advances in the management of acute myocardial infarction (MI), up to 38% of patients will experience signs of heart failure (HF) and many have a reduced left ventricular ejection fraction (LVEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented cardiovascular benefits. However, data are limited regarding their use after an acute MI.

Guest Authors: Amy Hu, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP, CDCES

Music by Good Talk